Inclusion complex of aprepitant with cyclodextrin: evaluation of physico-chemical and pharmacokinetic properties

References

• Cocquyt V, Van Belle S, Reinhardt RR, Decramer ML, O’Brien M, Schellens JH et al. (2001). Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis. Eur J Cancer, 37:835–842.
   PubMed Web of Science ®Google Scholar
• Navari RM, Reinhardt RR, Gralla RJ, Kris MG, Hesketh PJ, Khojasteh A et al. (1999). Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754,030 Antiemetic Trials Group. N Engl J Med, 340:190–195.
   PubMed Web of Science ®Google Scholar
• Campos D, Pereira JR, Reinhardt RR, Carracedo C, Poli S, Vogel C et al. (2001). Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone. J Clin Oncol, 19:1759–1767.
   PubMed Web of Science ®Google Scholar
• Van Belle S, Lichinitser MR, Navari RM, Garin AM, Decramer ML, Riviere A et al. (2002). Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869. Cancer, 94:3032–3041.
   PubMed Web of Science ®Google Scholar
• Antiemetic Subcommittee of the Multinational Association of supportive care in Cancer (MASCC). (1998). Prevention of chemotherapy and radiotherapy-induced emesis: Results of the Perugia Consensus Conference. Ann Oncol, 9:1022–1029.
   Web of Science ®Google Scholar
• Roila F, Tonato M, Ballatori E, Del Favero A. (1996). Comparative studies of various antiemetic regimens. Support Care Cancer, 4:270–280.
   PubMed Web of Science ®Google Scholar
• Grunberg SM, Deuson RR, Mavros P, Geling O, Hansen M, Cruciani G et al. (2004). Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. Cancer, 100:2261–2268.
   PubMed Web of Science ®Google Scholar
• Wu Y, Loper A, Landis E, Hettrick L, Novak L, Lynn K et al. (2004). The role of biopharmaceutics in the development of a clinical nanoparticle formulation of MK-0869: A Beagle dog model predicts improved bioavailability and diminished food effect on absorption in human. Int J Pharm, 285:135–146.
   PubMed Web of Science ®Google Scholar
• US FDA. (2000). Guidance for Industry: Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system.
   Google Scholar
• Löbenberg R, Amidon GL. (2000). Modern bioavailability, bioequivalence and biopharmaceutics classification system. New scientific approaches to international regulatory standards. Eur J Pharm Biopharm, 50:3–12.
   PubMed Web of Science ®Google Scholar
• Yasushi S, Ekarat J, Filippos K, Christos R, Jennifer BD. (2010). Forecasting in vivo oral absorption and food effect of micronized and nanosized aprepitant formulations in humans. Eur J Pharm Biopharm, 76:95–104.
   PubMed Web of Science ®Google Scholar
• Dhananjay SS, Seshasai MM, Gowthamrajanb K, Giriraj KT, Rajesh V, Parchuri SR. (2010). Optimization of formulation and process variable of nanosuspension: An industrial perspective. Int J Pharm, 402:213–220.
   PubMed Web of Science ®Google Scholar
• Müller RH, Jacobs C, Kayser O. (2001). Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future. Adv Drug Deliv Rev, 47:3–19.
   PubMed Web of Science ®Google Scholar
• Basa S, Muniyappan T, Karatgi P, Prabhu R, Pillai R. (2008). Production and in vitro characterization of solid dosage form incorporating drug nanoparticles. Drug Dev Ind Pharm, 34:1209–1218.
   PubMed Web of Science ®Google Scholar
• Aungst BJ. (1993). Novel formulation strategies for improving oral bioavailability of drugs with poor membrane permeation or presystemic metabolism. J Pharm Sci, 82:979–987.
   PubMed Web of Science ®Google Scholar
• Humberstone AJ, Charman WN. (1997). Lipid-based vehicles for the oral delivery of poorly water soluble drugs. Adv Drug Deliv Rev, 25:103–128.
   Web of Science ®Google Scholar
• Constantinides PP. (1995). Lipid microemulsions for improving drug dissolution and oral absorption: Physical and biopharmaceutical aspects. Pharm Res, 12:1561–1572.
   PubMed Web of Science ®Google Scholar
• Pouton CW. (2000). Lipid formulations for oral administration of drugs: Non-emulsifying, self-emulsifying and ‘self-microemulsifying’ drug delivery systems. Eur J Pharm Sci, 11 Suppl 2:S93–S98.
   PubMed Web of Science ®Google Scholar
• Davis ME, Brewster ME. (2004). Cyclodextrin-based pharmaceutics: Past, present and future. Nat Rev Drug Discov, 3:1023–1035.
   PubMed Web of Science ®Google Scholar
• Davis ME. (2009). Design and development of IT-101, a cyclodextrin-containing polymer conjugate of camptothecin. Adv Drug Deliv Rev, 61:1189–1192.
   PubMed Web of Science ®Google Scholar
• Vijaykumar N, Pradeep K, Srinivasarao P, Raviraj P. (2010). Drug product development and pharmacological evaluation of a sparingly soluble novel camptothecin analog for peroral administration. Drug Delivery, 18:294–303.
   Web of Science ®Google Scholar
• Loftsson T, Brewster ME. (1996). Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization. J Pharm Sci, 85:1017–1025.
   PubMed Web of Science ®Google Scholar
• Riley CM, Rytting JH, Kral MA. (1991). Higuchi Takeru: A memorial tribute, equilibria and thermodynamics. Vol. 3. Lawrence: Allen Press.
   Google Scholar
• Tomasik P, Schilling CH. (1998). Complexes of starch with inorganic guests. In: Horton D, ed. Advances in Carbohydrate Chemistry and Biochemistry. Vol. 53. San Diego: Academic Press, 263–243.
   Google Scholar
• Tomasik P, Schilling CH. (1998). Complexes of starch with organic guests. In: Horton D, ed. Advances in Carbohydrate Chemistry and Biochemistry. Vol. 53. San Diego: Academic Press, 345–426.
   Google Scholar
• Loftsson T, Hreinsdóttir D, Másson M. (2005). Evaluation of cyclodextrin solubilization of drugs. Int J Pharm, 302:18–28.
   PubMed Web of Science ®Google Scholar
• Chatjigakis AK, Donze C, Coleman AW. (1992). Solubility behavior of B-cyclodextrin in water/cosolvent mixtures. Anal Chem, 64:1632–1634.
   Web of Science ®Google Scholar
• Loftsson T, Hreindótter D, Másson M. (2007). The complexation efficiency. J Incl Phenom Macrocycl Chem, 57:545–552.
   Web of Science ®Google Scholar
• Ekarat J, Niels J, Christos R, Jennifer BD. (2008). Dissolution Media Simulating Conditions in the Proximal Human Gastrointestinal Tract: An Update. Pharm Res, 25:1663–1676.
   PubMed Web of Science ®Google Scholar
• Manolikar MK, Sawant MR. (2003). Study of solubility of isoproturon by its complexation with beta-cyclodextrin. Chemosphere, 51:811–816.
   PubMed Web of Science ®Google Scholar
• Fernandes CM, Teresa Vieira M, Veiga FJ. (2002). Physicochemical characterization and in vitro dissolution behavior of nicardipine-cyclodextrins inclusion compounds. Eur J Pharm Sci, 15:79–88.
   PubMed Web of Science ®Google Scholar
• Loukas YL, Vraka V, Gregoriadis G. (1998). Drugs, in cyclodextrins in liposomes: A novel approach to the chemical stability of drugs sensitive to hydrolysis. Int J Pharm, 162:137–142.
   Web of Science ®Google Scholar
• Louise C, James M. (2000). Polymorphic from of a tachykinin receptor antagonist. US patent No. 6,096,742.
   Google Scholar